Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shaofang Wu

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
Neuro-Oncology Advances|January 12, 2024
MGMT function determines the differential response of ATR inhibitors with DNA-damaging agents in glioma stem cells for GBM therapyVincent W S Leong, Sabbir Khan, Pratibha Sharma, et al.
Oncotarget|April 21, 2017
Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant gliomaDimpy Koul, Shuzhen Wang, Shaofang Wu, et al.
Cancer Research|August 17, 2019
Tie2-FGFR1 Interaction Induces Adaptive PI3K Inhibitor Resistance by Upregulating Aurora A/PLK1/CDK1 Signaling in GlioblastomaXiaolong Li, Emmanuel Martinez-Ledesma, Chen Zhang, et al.
Oncotarget|March 15, 2018
The polo-like kinase 1 inhibitor volasertib synergistically increases radiation efficacy in glioma stem cellsJianwen Dong, Soon Young Park, Nghi Nguyen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2019
<i>EGFR</i> Amplification Induces Increased DNA Damage Response and Renders Selective Sensitivity to Talazoparib (PARP Inhibitor) in GlioblastomaShaofang Wu, Feng Gao, Siyuan Zheng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 5, 2019
Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II TrialPatrick Y Wen, Mehdi Touat, Brian M Alexander, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
Neuro-Oncology Advances|January 12, 2024
MGMT function determines the differential response of ATR inhibitors with DNA-damaging agents in glioma stem cells for GBM therapyVincent W S Leong, Sabbir Khan, Pratibha Sharma, et al.
Oncotarget|April 21, 2017
Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant gliomaDimpy Koul, Shuzhen Wang, Shaofang Wu, et al.
Cancer Research|August 17, 2019
Tie2-FGFR1 Interaction Induces Adaptive PI3K Inhibitor Resistance by Upregulating Aurora A/PLK1/CDK1 Signaling in GlioblastomaXiaolong Li, Emmanuel Martinez-Ledesma, Chen Zhang, et al.
Oncotarget|March 15, 2018
The polo-like kinase 1 inhibitor volasertib synergistically increases radiation efficacy in glioma stem cellsJianwen Dong, Soon Young Park, Nghi Nguyen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2019
<i>EGFR</i> Amplification Induces Increased DNA Damage Response and Renders Selective Sensitivity to Talazoparib (PARP Inhibitor) in GlioblastomaShaofang Wu, Feng Gao, Siyuan Zheng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 5, 2019
Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II TrialPatrick Y Wen, Mehdi Touat, Brian M Alexander, et al.
Pageof 4